Selective Serotonin Reuptake Inhibitors in the Acute Treatment of Depression

Stuart A. Montgomery
Academic Department of Psychiatry
St Mary's Hospital Medical School
London W21NY, United Kingdom.


1. Altamura AC, Montgomery SA. Fluoxetine dose, pharmacokinetics and clinical efficacy. Rev Contemp Pharmacother 1990;1:75–81.

2. Amin MM, Anath JV, Coleman BS, et al. Fluvoxamine: antidepressant effect confirmed in a placebo controlled international study. Clin Neuropharmacol 1984;7(Suppl 1):317–318.

3. Andersen J, Bech P, Benjaminsen S, et al. Citalopram: clinical effect profiles in comparison with clomipramine. A controlled multicentre study. Psychopharmacologia 1986;90:131–138.

4. Aranow RB, Hudson JI, Pope HG, et al. Elevated antidepressant levels after addition of fluoxetine. Am J Psychiatry 1989;146:911–913.

5. Asberg M, Traskman L, Thoren P, Bertilsson L, Ringberger V-A. "Serotonin depression": A biochemical subgroup within the affective disorders? Science 1976;191:478–480.

6. Baldwin D, Fineberg NA, Montgomery SA. Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol 1991;6(Suppl 1):51–58.

7. Baumann P, Bertschy G. Pharmacodynamic and pharmacokinetic interactions of selective serotonin re-uptake inhibiting antidepressants (SSRIs) with other psychotropic drugs. Nord J Psychiatry 1993;47(Suppl 30):13–19.

8. Beasley CM, Dornseif BE, Bosomworth JC. Fluoxetine and suicidality: absence of association in controlled depression trials. Br Med J 1991;303:685–692.

9. Bech P, Cialdella P. Citalopram in depression: meta-analysis of intended and unintended effects. Int Clin Psychopharmacol 1992;6(5):45–54.

10. Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989;146:1352–1353.

11. Brod TM: Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989;146:1353.

12. Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. Br Med J 1987;295:1021–1024.

13. Claghorn J. A double-blind comparison of paroxetine and placebo in the treatment of depressed outpatients. Int Clin Psychopharmacol 1992;6(Suppl 4):25–41.

14. Committee on Safety of Medicines. Fluvoxamine and fluoxetine—interaction with monoamine oxidase inhibitors, lithium and tryptophan. Curr Prob 1989;26.

15. Committee on Safety of Medicines. Dystonia and withdrawal symptoms with paroxetine (Seroxat). Curr Prob 1993;19:1.

16. Conti L, Dell'Osso LRF, Mussetti L, Cassano GB. Fluvoxamine maleate: double-blind clinical trial vs placebo in hospitalized depressed patients. Curr Ther Res 1988;43:468–480.

17. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262–265.

18. Dasgupta K. Additional case of suicidal ideation associated with fluoxetine. Am J Psychiatry 1990;147:1570.

19. Dillier N. Worldwide clinical experience with Ludiomil. Activ Nerv Sup 1982;24:40–52.

20. Dominguez RA, Goldstein BJ, Jacobson AF, et al. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. J Clin Psychiatry 1985;46:84–87.

21. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217–222.

22. Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry 1991;159:394–398.

23. Dunbar GC, Fuell DL. The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. Int Clin Psychopharmacol 1992;6(Suppl 4):81–90.

24. Fabre LF. A double-blind multicenter study comparing the safety and efficacy of sertraline with placebo in major depression. Biol Psychiatry 1991;29:353S.

25. Fabre LF, Crismon L. Efficacy of fluoxetine in outpatients with major depression. Curr Ther Res 1985;37:115–123.

26. Feighner J, Boyer WF, Meredith CH, Hendrickson GG. A placebo-controlled inpatients comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 1989;4:239–244.

27. Geltzer J. Limits to chemotherapy of depression. Psychopathology 1986;19:108–117.

28. Glassman AH, Bigger JT. Cardovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch Gen Psychiatry 1981;38:815–820.

29. Heiligenstein JH, Tollefson GD, Faries DE. A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DM-III-R major depression and melancholia. Int Clin Psychopharmacol 1993;8: 247–251.

30. Inman WH. Paroxetine and dystonia. Pharmaceut J 1993;303.

31. Itil TM, Shrivastava RK, Mukherjee S, Coleman BS, Michael ST: A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. Br J Clin Pharmacol 1983;15(Suppl 3):433–438.

32. Jenner PN. Paroxetine: an overview of dosage, tolerability, and safety. Int Clin Psychopharmacol 1992;6(Suppl 4):69–80.

33. Johnson DAW. Depression: treatment compliance in general practice. Acta Psychiatr Scand 1981;63(Suppl 290):447–453.

34. Lapierre YD, Browne M, Horn E, et al. Treatment of major affective disorder with fluvoxamine. J Clin Psychiatry 1987;48:65–68.

35. Levinson ML, Lipsky RJ, Fuller DK. Adverse effects and drug interactions associated with fluoxetine therapy. Ann Pharmacother 1991;25:657–661.

36. Lydiard RB, Laird LK, Morton WA, et al. Fluvoxamine, imipramine and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull 1989;25:68–70.

37. March JS, Kobak KA, Jefferson JW. A double-blind, placebocontrolled trial of fluvoxamine versus imipramine in outpatients with major depression. J Clin Psychiatry 1990;51:200–202.

38. Masand P, Gupta S, Dewan M. Suicidal ideation related to fluoxetine treatment. New Engl J Med 1991;324:420.

39. Mendels J, Fabre L, Kiev A. A double blind placebo controlled study of citalopram in major depressive disorder. NCDEU (Florida) 1990; (abst).

40. Mendlewicz J. Efficacy of fluvoxamine in severe depression. Drugs 1992;43(Suppl 2):32–39.

41. Montgomery SA. The efficacy of fluoxetine as an antidepressant in the short and long term. Int Clin Psychopharmacol 1989;4(Suppl 1):113–119.

42. Montgomery SA. Suicide and antidepressants. Drugs 1992;43 (Supp 2):24–31.

43. Montgomery SA: The advantages of paroxetine in different subgroups of depression. Int Clin Psychopharmacol 1992;6(Suppl 4):91–100.

44. Montgomery SA. A review of the safety of paroxetine. Eur Psychiatry 1993;8(Suppl 1):25–30.

45. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988;153 (Suppl 3):69–76.

46. Montgomery SA, Dunbar GC. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189–195.

47. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47–53.

48. Montgomery SA, McAulay R, Rani SJ, Roy D, Montgomery DB. A double blind comparison of zimelidine and amitriptyline in endogenous depression. Acta Psychiatr Scand 1981;63(Suppl 290): 314–327.

49. Montgomery SA, Pinder RM. Do some antidepressants promote suicide. Psychopharmacologia 1987;92:265–266.

50. Montgomery SA, Rasmussen JGC, Lyby K, Connor P, Tanghoj P. Dose response relationship of citalopram 20 mg, citalopram 40 mg, and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 1992;6(Suppl 5):65–70.

51. Montgomery SA, Rasmussen JGC, Tanghoj P. A 24 week study of 20 mg citalopram, 40 mg citalopram and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181–188.

52. Muijen M, Roy D, Silverstone T, Mehmet A, Christie M. A comparative clinical trial of fluoxetine, mianserin and placebo with depressed outpatients. Acta Psychiatr Scand 1988;78:384–390.

53. Norton KRW, Sireling LI, Bhat AV, Rao B, Paykel ES. A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients. J Affect Dis 1984;7:297–308.

54. Pande AC, Sayler ME. Severity of depression and response to fluoxetine. Int Clin Psychopharmacol 1993;8:243–245.

55. Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant efficacy of sertraline: a double-blind placebo- and amitriptylinecontrolled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990;51:18–27.

56. Rickels K, Amsterdam JD, Avallone MF. Fluoxetine in major depression—a controlled study. Curr Ther Res 1986;39:559–563.

57. Rosenbaum JF, Quitkin FM, Fava M, et al. Fluoxetine vs placebo: long-term treatment of MDD. Proceedings of the American College of Neuropsychopharmacology Annual Meeting. Hawaii 1993;32 (abst).

58. Roth D, Mattes J, Sheenan KH, Sheenan DV. A double blind comparison of fuvoxamine, desipramine and placebo in out-patients with depression. Prog Neuropsychopharm Biol Psychiat 1990;14: 929–939.

59. Shaw DM, Harris B, Lloyd AT, et al. A comparison of the antidepressant action of citalopram and amitriptyline. Br J Psychiatry 1986;149:515–517.

60. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985;46:53–58.

61. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148: 705–713.

62. Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1989;146:399–400.

63. Teicher MH, Glod C, Cole JO. The emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:207–210.

64. van Praag HM, Korf J. Endogenous depressions with and without disturbances of 5-hydroxytryptamine metabolism: a biochemical classification? Psychopharmacologia 1971;19:148–152.

65. Vandel S, Bertschy G, Bonin B, et al. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology 1992; 25:202–207.

66. Wakelin JS. The role of serotonin in depression and suicide: do serotonin reuptake inhibitors provide a key? Adv Biol Psychiatry 1988;17:70–83.

67. Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M. Low dose fluoxetine therapy for depression. Psychopharmacol Bull 1988;24:183–188.

68. Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 1987;23: 164–168.

69. Zhang X, Peng L, Chen Y, Hertz L. Stimulation of glycogenolysis in astrocytes by fluoxetine, and antidepressant acting like 5-HT. NeuroRep 1993;4:1235–1238.

Back to Chapter

published 2000